Scribd
Upload
14 views1 page

CPHL Material

Citi Pharma Limited announces that its subsidiary, Citi Veterinary Limited, has begun trading operations with an initial launch of 32 veterinary products, including vaccines. The company projects a turnover of PKR 1,500 million for the financial year 2025-26 and plans to scale operations to reach PKR 10 billion in three years. Additionally, Citi Veterinary Limited is establishing Pakistan's first dedicated veterinary API plant and expects to increase its gross profit margin to approximately 25% upon commencing in-house production.

Uploaded by

Kk
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
14 views1 page

CPHL Material

Citi Pharma Limited announces that its subsidiary, Citi Veterinary Limited, has begun trading operations with an initial launch of 32 veterinary products, including vaccines. The company projects a turnover of PKR 1,500 million for the financial year 2025-26 and plans to scale operations to reach PKR 10 billion in three years. Additionally, Citi Veterinary Limited is establishing Pakistan's first dedicated veterinary API plant and expects to increase its gross profit margin to approximately 25% upon commencing in-house production.

Uploaded by

Kk
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Citi Pharma Limited

The General Manager September 12, 2025


Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi .

DISCLOSURE OF MATERIAL INFORMATION

Dear Sir

In compliance with Section96 of the Securities Act, 20 15 andclause5.6.1 of the PSXRegulations, we herebY conveY the following
information .

citi Pharma Limited is pleased to announce that its wholly owned subsidiary, Citi Veterinary Limited, has formally commenced
trading operations. The Compdny is initially launching 32 veterinaryproducts including vaccines, with Letters of Credit (LCs)
already eslablished for 8 products to ensure timely availability and suppIY.

For the financial year 2025-26J Citi Veterinary Limited is projectingan expected turnoverof approximately PKR 1,500million with
a grosspr,.)Htmargin of 13%. The Company’s strong and long-standing supply partnerships in China will play a vital role in ensuring
consistent and reliable supply dvailab j]ity in Pakistdn’s veterinaryhealthcare market.Oursupply chain partnersin China have
already established dedicated veterinarydivisions andhave strongly encouragedCiti Veterinary Limited to tap into Pakistan’s
veterinary sector. Looking ahead) Citi Veterinary Limited is ambitiously planning to scale operations and achieve a turnover target
of PKR IQ billion within the next three years.

On the productionside, Citi Veterinary Limited has already submittedthe laYout plan with the Drug RegulatorY AuthoritYof
Pakistan (DRAP) and the inspection is expected to be held in December 2025. Allied facilities are already in place, andthe Colnpany
has acquired locally manufactured machinery while also establishingLCs for the import of additional machinery.With these
measures in place,the production facility is expected to be ready for use, with trial production commencingbY the endof Q4 of FY
2025-26 and the commercial production initiating from the start of FY 2026-27. Furthermore, the CompanY is planning to establish
Pakistan-s first dedicatedveterinaryAPI plant during FY 2026-27, marking a pioneeringstep in the countrY’s veteEinalj'

pharmaceutical indUstI}/

Upon commencement of in-house production, the Company anticipates an increase in its gross profit margin to approximateIY 25%.
renecring stronger value addition and enhanced operational efficiency.

Citi Veterinary Limited is confidentthatthis milestone will mark the beginning of a new growthchapter, contributingsignificantly
to Pakistan’s veterinary<RRdrmdceutical industry andfurther strengthening Citi Pharma Limited’s diversifiedportfolio
in\
Sincerely

CC:
Ghulam Dastgeerl ExecutiveDirector/HOD
Company Secretary Offsite-II Department, SupervisionDivision
63-NIC Building, Jinnah Avenue
Islamabad

B 588 - Q, Johar Town. Lahore - Pakistan A 3KM. Head Ba11okiRoad. Phool Nagar, District Kasur - Pakistan

@ Head Office : +92.42. 35316587 - 90 1 Factory: +92.49. 4510189, +92.49. 4513392 @ www.dtipharma.com.pk

You might also like